Cormorant Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cormorant Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.68M	Sell	125,000 -125,000	-50%	-$4.65M	0.24%	39
2026 Q1	$9.08M	Sell	250,000 -50,000	-17%	-$2.23M	0.46%	36
2025 Q4	$14M	Sell	300,000 -100,000	-25%	-$4.45M	0.65%	28
2025 Q3	$16.7M	Hold	400,000	–	–	1.15%	22
2025 Q2	$11.5M	Sell	400,000 -200,000	-33%	-$6.18M	0.86%	25
2025 Q1	$20.1M	Sell	600,000 -400,000	-40%	-$14.9M	1.51%	21
2024 Q4	$51.1M	Sell	1,000,000 -100,000	-9%	-$5.59M	2.81%	9
2024 Q3	$56.2M	Sell	1,100,000 -250,000	-19%	-$12.9M	2.98%	8
2024 Q2	$60.5M	Buy	1,350,000 +200,000	+17%	+$9.24M	3.49%	8
2024 Q1	$53.8M	Hold	1,150,000	–	–	2.36%	11
2023 Q4	$40.9M	Buy	1,150,000 +48,096	+4%	+$1.47M	1.95%	15
2023 Q3	$32.8M	Buy	+1,101,904	New	+$22.7M	1.91%	14

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cormorant Asset Management's CRNX Position: Q2 2026 in Review

Cormorant Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 50% in Q2 2026, selling an estimated $4.65M and leaving 125,000 shares worth $4.68M. The position accounts for 0.24% of the portfolio, ranked #39.

Cormorant Asset Management first reported a position in CRNX in Q3 2023 and has held it in 12 quarters since. The position peaked at $60.5M in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Cormorant Asset Management held 125,000 shares of Crinetics Pharmaceuticals worth $4.68M as of Q2 2026.
Cormorant Asset Management sold 125,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $4.65M.
Crinetics Pharmaceuticals made up 0.24% of Cormorant Asset Management's portfolio in Q2 2026, its #39 holding.
Cormorant Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Cormorant Asset Management's Crinetics Pharmaceuticals position peaked at $60.5M in Q2 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.